{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=70",
    "query": {
      "condition": "Skin Disorders",
      "page": 70
    },
    "page_size": 10
  },
  "pagination": {
    "page": 70,
    "page_size": 10,
    "total_count": 16135,
    "total_pages": 1614,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=71&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=69&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T14:17:06.122Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00121836",
      "title": "A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 109,
      "start_date": "2005-06",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2011-04-27",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Burbank, California • Glendale, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121836"
    },
    {
      "nct_id": "NCT04146363",
      "title": "Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 424,
      "start_date": "2019-09-24",
      "completion_date": "2022-05-03",
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 30,
      "location_summary": "Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04146363"
    },
    {
      "nct_id": "NCT00963508",
      "title": "Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediculosis"
      ],
      "interventions": [
        {
          "name": "Malathion gel 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Permethrin 1% rinse (Nix Crème)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 403,
      "start_date": "2009-08",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-06-13",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 7,
      "location_summary": "Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963508"
    },
    {
      "nct_id": "NCT03351140",
      "title": "Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Qualitative Interviews",
          "type": "OTHER"
        },
        {
          "name": "PROMIS Physical Function Items",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-12-20",
      "completion_date": "2020-05-08",
      "has_results": false,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 1,
      "location_summary": "Mountlake Terrace, Washington",
      "locations": [
        {
          "city": "Mountlake Terrace",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03351140"
    },
    {
      "nct_id": "NCT00320710",
      "title": "Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 416,
      "start_date": "2006-02",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2014-08-22",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 92,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Springdale, Arkansas + 81 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00320710"
    },
    {
      "nct_id": "NCT00005023",
      "title": "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "HER-2/neu peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-03",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-30",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005023"
    },
    {
      "nct_id": "NCT03929224",
      "title": "The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Infection"
      ],
      "interventions": [
        {
          "name": "Medicinal honey",
          "type": "DRUG"
        },
        {
          "name": "Bacitracin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17,
      "start_date": "2018-10-25",
      "completion_date": "2020-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 1,
      "location_summary": "Novi, Michigan",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03929224"
    },
    {
      "nct_id": "NCT05728879",
      "title": "Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cutaneous T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "APR-TD011 (RLF-TD011)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2027-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05728879"
    },
    {
      "nct_id": "NCT01797562",
      "title": "Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allergic Contact Dermatitis"
      ],
      "interventions": [
        {
          "name": "Panels 1.3, 2.2 and 3.2 experimental allergens",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Allerderm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 116,
      "start_date": "2012-12-10",
      "completion_date": "2015-09-08",
      "has_results": true,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Aurora, Colorado • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01797562"
    },
    {
      "nct_id": "NCT03517488",
      "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Breast Carcinoma",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Endometrial Carcinoma",
        "Mesothelioma",
        "Neuroendocrine Carcinoma",
        "Cervical Cancer",
        "Small Cell Lung Carcinoma",
        "Squamous Cell Carcinoma of the Anus",
        "Castration-Resistant Prostate Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Cholangiocarcinoma",
        "Basal Cell Carcinoma",
        "Ovarian Carcinoma",
        "Fallopian Tube Carcinoma",
        "Thymoma",
        "Thymic Carcinoma",
        "Squamous Cell Carcinoma of the Penis",
        "Vulvar Carcinoma",
        "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy",
        "Malignant Adnexal Neoplasms",
        "Non-squamous Cell Salivary Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb20717",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2018-07-10",
      "completion_date": "2022-09-06",
      "has_results": false,
      "last_update_posted_date": "2022-12-01",
      "last_synced_at": "2026-11-08T14:17:06.122Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03517488"
    }
  ]
}